Oral Rivaroxaban for Symptomatic Venous Thromboembolism

Rupert Bauersachs , Scott D. Berkowitz , Benjamin Brenner , Rupert Bauersachs , Scott D. Berkowitz , Benjamin Brenner , Harry R. Büller , Hervé Decousus , Alexander Gallus , Anthonie W.A. Lensing , Frank Misselwitz , Martin H. Prins , Gary E. Raskob , Annelise Segers , Peter Verhamme , Philip S. Wells , Giancarlo Agnelli , Henri Bounameaux , Alexander T. Cohen , Bruce L. Davidson , Franco Piovella , Sebastian Schellong , Dominique Mottier
2010 New England Journal of Medicine 3,179 citations

Abstract

Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation. (Funded by Bayer Schering Pharma and Ortho-McNeil; ClinicalTrials.gov numbers, NCT00440193 and NCT00439725.).

Keywords

RivaroxabanMedicineVitamin K antagonistEdoxabanWarfarinVenous thrombosisPlaceboAnesthesiaSurgeryRandomized controlled trialThrombosisInternal medicineAtrial fibrillation

Affiliated Institutions

Related Publications

Publication Info

Year
2010
Type
article
Volume
363
Issue
26
Pages
2499-2510
Citations
3179
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3179
OpenAlex

Cite This

Rupert Bauersachs, Scott D. Berkowitz, Benjamin Brenner et al. (2010). Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine , 363 (26) , 2499-2510. https://doi.org/10.1056/nejmoa1007903

Identifiers

DOI
10.1056/nejmoa1007903